Advertisement
The award recognizes CorMatrix's contribution to the cardiovascular marketthrough its involvement in the research, development and marketing of its ECMTechnology(TM) for pericardial closure and cardiac tissue repair.
Advertisement
"Frost & Sullivan acknowledges CorMatrix's dedication in the developmentof the unique ECM Technology(TM). Through this unique technology the companystrives to meet the ever growing demand and continuous innovation thatcharacterizes the cardiac device market," said Frost & Sullivan industryanalyst Archana Swathy. "This exceptional product enhances the patient'srecovery after surgery by facilitating efficient tissue repair."
The company's ECM Technology(TM) product acts as a scaffold into which thepatient's own cells migrate and integrate, stimulating the body's innatewound-healing mechanisms to repair tissue at the site of implantation. As thepatient's cells populate the matrix, they lay down their own collagen, whichmatures over time to form a functional tissue repair. The implanted ECMmaterial is gradually replaced and resorbed by the body as the patient'stissue is remodeled.
"We are honored to be presented with this Award, as the recognitionfurther validates the increasing interest and acceptance that our ECMTechnology(TM) continues to receive within the clinical community," commentedBeecher Lewis, President and Chief Operating Officer of CorMatrixCardiovascular.
The use of extracellular matrix technology in non-cardiovascularapplications has established a significant foothold in soft tissue repair,wound management and orthopedic applications. Since the launch of CorMatrix'sECM for Pericardial Closure, the technology has been used at more than 220hospitals across the U.S. and has been implanted in more than 9,000 cardiacprocedures.
About CorMatrix ECM Technology(TM)
CorMatrix Cardiovascular holds an exclusive license from Purdue Universityto research, develop, manufacture and market naturally occurring ECM productsfor cardiovascular applications. The company currently has U.S. clearance andEuropean approval with a CE Mark to market its ECM Technology as an implantfor pericardial closure, clearance in the U.S. for cardiac tissue repair, andis conducting preclinical studies on a number of cardiovascular applicationsincluding an emulsified, injectible form of its ECM Technology as a potentialtreatment for heart failure.
About CorMatrix Cardiovascular, Inc.
CorMatrix Cardiovascular, a privately held company based in Atlanta,Georgia, is dedicated to developing and delivering innovative biomaterialdevices that harness the body's own innate ability to regenerate damaged hearttissue. For more information visit http://www.cormatrix.com.
SOURCE CorMatrix Cardiovascular Inc.
